Until recently, docetaxel-based therapy represented the only therapy shown to prolong survival in patients with metastatic castration-resistant prostate cancer （mCRPC）. The past year and a half has been marked by un...Until recently, docetaxel-based therapy represented the only therapy shown to prolong survival in patients with metastatic castration-resistant prostate cancer （mCRPC）. The past year and a half has been marked by unprecedented progress in treatments for this disease. Three positive phase III clinical trials have emerged, each evaluating agents （sipuleuceI-T, cabazitaxel and abiraterone） with distinct mechanisms of action. Herein, the three pivotal trials are described alongside both past and current large phase III studies conducted in this mCRPC. The overall survival for patients with mCRPC treated in current clinical trials is considerably longer than noted in the past. We note that more recent trials with older agents have also shown improved survival and discuss potential non-therapeutic biases that influence this critical measure of outcome. The necessity for utilizing randomized trials when evaluating new therapeutics is emphasized given the changing prognosis in this mCRPC.展开更多
Dendreon公司研究者日前公布其PROTECT （PROvenge Treatment and Early Cancer Treatment）（或P-11 Ⅲ期）研究数据，结果显示Provenge（R）（sipuleueel-T）（Ⅰ）能诱导可持续的长期免疫记忆反应并在加强免疫后可得以保持。研究结...Dendreon公司研究者日前公布其PROTECT （PROvenge Treatment and Early Cancer Treatment）（或P-11 Ⅲ期）研究数据，结果显示Provenge（R）（sipuleueel-T）（Ⅰ）能诱导可持续的长期免疫记忆反应并在加强免疫后可得以保持。研究结果同时提示，一疗效的衡量指标——抗原提呈细胞（APCs）上的CD54上调与免疫激活相关。展开更多
文摘Until recently, docetaxel-based therapy represented the only therapy shown to prolong survival in patients with metastatic castration-resistant prostate cancer （mCRPC）. The past year and a half has been marked by unprecedented progress in treatments for this disease. Three positive phase III clinical trials have emerged, each evaluating agents （sipuleuceI-T, cabazitaxel and abiraterone） with distinct mechanisms of action. Herein, the three pivotal trials are described alongside both past and current large phase III studies conducted in this mCRPC. The overall survival for patients with mCRPC treated in current clinical trials is considerably longer than noted in the past. We note that more recent trials with older agents have also shown improved survival and discuss potential non-therapeutic biases that influence this critical measure of outcome. The necessity for utilizing randomized trials when evaluating new therapeutics is emphasized given the changing prognosis in this mCRPC.
文摘Dendreon公司研究者日前公布其PROTECT （PROvenge Treatment and Early Cancer Treatment）（或P-11 Ⅲ期）研究数据，结果显示Provenge（R）（sipuleueel-T）（Ⅰ）能诱导可持续的长期免疫记忆反应并在加强免疫后可得以保持。研究结果同时提示，一疗效的衡量指标——抗原提呈细胞（APCs）上的CD54上调与免疫激活相关。
